As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential campaign — and what their hopes are for a new presidential administration. Read an excerpt from each below.
“What Sandoz CEO Richard Saynor is thinking about the 2024 elections”
With all eyes currently on the upcoming U.S. elections, it’s easy to forget that this year more than 75 countries have headed to the polls or will soon. That includes eight of the world’s 10 most populous nations, with some 4 billion eligible voters, plus the 27-nation European Parliament.
While health care has hardly topped the 2024 political agenda, two common themes in both the U.S. presidential campaign and in other elections worldwide have emerged: increasing support for protectionist economic policies and growing concerns about inflation — not least the (increasingly) high prices of branded medicines.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
